IL17A and cancer: Tumors with a good-TiME signature were enriched for partially exhausted CD8+ T cells that have enhanced capacity to release IFN-γ, activated pDC, HLA-DR+ cancer cells, and decreased numbers of IL-10– and IL-17–releasing Tregs and PD-L1+ TAM.